Report cover image

Global Varicella Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 196 Pages
SKU # APRC20552940

Description

Summary

According to APO Research, The global Varicella Live Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Varicella Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Varicella Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Varicella Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Varicella Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Varicella Live Vaccine include Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Panacea Biotec, Mitsubishi Tanabe Pharma Corporation and MedImmune, LLC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Varicella Live Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Varicella Live Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Varicella Live Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Varicella Live Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Varicella Live Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Varicella Live Vaccine sales, projected growth trends, production technology, application and end-user industry.

Varicella Live Vaccine Segment by Company

Johnson & Johnson
Merck & Co., Inc.
Pfizer, Inc.
GlaxoSmithKline plc
Serum Institute of India Pvt. Ltd.
Sanofi Pasteur
Panacea Biotec
Mitsubishi Tanabe Pharma Corporation
MedImmune, LLC
Emergent BioSolutions, Inc.
Daiichi Sankyo
CSL Limited
Biological E
Bavarian Nordic
Astellas Pharma Inc.
Varicella Live Vaccine Segment by Type

Monovalent Vaccines
Multivalent Vaccines
Varicella Live Vaccine Segment by Application

Herpes Zoster Immunization
Measles Immunization
Chicken Pox Immunization
Others
Varicella Live Vaccine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Varicella Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Live Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Live Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Varicella Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Varicella Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Varicella Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Varicella Live Vaccine Market Size, 2020 VS 2024 VS 2031
1.3 Global Varicella Live Vaccine Market Size Estimates and Forecasts (2020-2031)
1.4 Global Varicella Live Vaccine Sales Estimates and Forecasts (2020-2031)
1.5 Global Varicella Live Vaccine Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Varicella Live Vaccine Market Dynamics
2.1 Varicella Live Vaccine Industry Trends
2.2 Varicella Live Vaccine Industry Drivers
2.3 Varicella Live Vaccine Industry Opportunities and Challenges
2.4 Varicella Live Vaccine Industry Restraints
3 Varicella Live Vaccine Market by Manufacturers
3.1 Global Varicella Live Vaccine Revenue by Manufacturers (2020-2025)
3.2 Global Varicella Live Vaccine Sales by Manufacturers (2020-2025)
3.3 Global Varicella Live Vaccine Average Sales Price by Manufacturers (2020-2025)
3.4 Global Varicella Live Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Varicella Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Varicella Live Vaccine Manufacturers, Product Type & Application
3.7 Global Varicella Live Vaccine Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Varicella Live Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Varicella Live Vaccine Players Market Share by Revenue in 2024
3.8.3 2024 Varicella Live Vaccine Tier 1, Tier 2, and Tier 3
4 Varicella Live Vaccine Market by Type
4.1 Varicella Live Vaccine Type Introduction
4.1.1 Monovalent Vaccines
4.1.2 Multivalent Vaccines
4.2 Global Varicella Live Vaccine Sales by Type
4.2.1 Global Varicella Live Vaccine Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Varicella Live Vaccine Sales by Type (2020-2031)
4.2.3 Global Varicella Live Vaccine Sales Market Share by Type (2020-2031)
4.3 Global Varicella Live Vaccine Revenue by Type
4.3.1 Global Varicella Live Vaccine Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Varicella Live Vaccine Revenue by Type (2020-2031)
4.3.3 Global Varicella Live Vaccine Revenue Market Share by Type (2020-2031)
5 Varicella Live Vaccine Market by Application
5.1 Varicella Live Vaccine Application Introduction
5.1.1 Herpes Zoster Immunization
5.1.2 Measles Immunization
5.1.3 Chicken Pox Immunization
5.1.4 Others
5.2 Global Varicella Live Vaccine Sales by Application
5.2.1 Global Varicella Live Vaccine Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Varicella Live Vaccine Sales by Application (2020-2031)
5.2.3 Global Varicella Live Vaccine Sales Market Share by Application (2020-2031)
5.3 Global Varicella Live Vaccine Revenue by Application
5.3.1 Global Varicella Live Vaccine Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Varicella Live Vaccine Revenue by Application (2020-2031)
5.3.3 Global Varicella Live Vaccine Revenue Market Share by Application (2020-2031)
6 Global Varicella Live Vaccine Sales by Region
6.1 Global Varicella Live Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Varicella Live Vaccine Sales by Region (2020-2031)
6.2.1 Global Varicella Live Vaccine Sales by Region (2020-2025)
6.2.2 Global Varicella Live Vaccine Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Varicella Live Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Varicella Live Vaccine Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Varicella Live Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Varicella Live Vaccine Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Varicella Live Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Varicella Live Vaccine Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Varicella Live Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Varicella Live Vaccine Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Varicella Live Vaccine Revenue by Region
7.1 Global Varicella Live Vaccine Revenue by Region
7.1.1 Global Varicella Live Vaccine Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Varicella Live Vaccine Revenue by Region (2020-2025)
7.1.3 Global Varicella Live Vaccine Revenue by Region (2026-2031)
7.1.4 Global Varicella Live Vaccine Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Varicella Live Vaccine Revenue (2020-2031)
7.2.2 North America Varicella Live Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Varicella Live Vaccine Revenue (2020-2031)
7.3.2 Europe Varicella Live Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Varicella Live Vaccine Revenue (2020-2031)
7.4.2 Asia-Pacific Varicella Live Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Varicella Live Vaccine Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Varicella Live Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Johnson & Johnson
8.1.1 Johnson & Johnson Comapny Information
8.1.2 Johnson & Johnson Business Overview
8.1.3 Johnson & Johnson Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Johnson & Johnson Varicella Live Vaccine Product Portfolio
8.1.5 Johnson & Johnson Recent Developments
8.2 Merck & Co., Inc.
8.2.1 Merck & Co., Inc. Comapny Information
8.2.2 Merck & Co., Inc. Business Overview
8.2.3 Merck & Co., Inc. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Merck & Co., Inc. Varicella Live Vaccine Product Portfolio
8.2.5 Merck & Co., Inc. Recent Developments
8.3 Pfizer, Inc.
8.3.1 Pfizer, Inc. Comapny Information
8.3.2 Pfizer, Inc. Business Overview
8.3.3 Pfizer, Inc. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Pfizer, Inc. Varicella Live Vaccine Product Portfolio
8.3.5 Pfizer, Inc. Recent Developments
8.4 GlaxoSmithKline plc
8.4.1 GlaxoSmithKline plc Comapny Information
8.4.2 GlaxoSmithKline plc Business Overview
8.4.3 GlaxoSmithKline plc Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 GlaxoSmithKline plc Varicella Live Vaccine Product Portfolio
8.4.5 GlaxoSmithKline plc Recent Developments
8.5 Serum Institute of India Pvt. Ltd.
8.5.1 Serum Institute of India Pvt. Ltd. Comapny Information
8.5.2 Serum Institute of India Pvt. Ltd. Business Overview
8.5.3 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Product Portfolio
8.5.5 Serum Institute of India Pvt. Ltd. Recent Developments
8.6 Sanofi Pasteur
8.6.1 Sanofi Pasteur Comapny Information
8.6.2 Sanofi Pasteur Business Overview
8.6.3 Sanofi Pasteur Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Sanofi Pasteur Varicella Live Vaccine Product Portfolio
8.6.5 Sanofi Pasteur Recent Developments
8.7 Panacea Biotec
8.7.1 Panacea Biotec Comapny Information
8.7.2 Panacea Biotec Business Overview
8.7.3 Panacea Biotec Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Panacea Biotec Varicella Live Vaccine Product Portfolio
8.7.5 Panacea Biotec Recent Developments
8.8 Mitsubishi Tanabe Pharma Corporation
8.8.1 Mitsubishi Tanabe Pharma Corporation Comapny Information
8.8.2 Mitsubishi Tanabe Pharma Corporation Business Overview
8.8.3 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Mitsubishi Tanabe Pharma Corporation Varicella Live Vaccine Product Portfolio
8.8.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
8.9 MedImmune, LLC
8.9.1 MedImmune, LLC Comapny Information
8.9.2 MedImmune, LLC Business Overview
8.9.3 MedImmune, LLC Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 MedImmune, LLC Varicella Live Vaccine Product Portfolio
8.9.5 MedImmune, LLC Recent Developments
8.10 Emergent BioSolutions, Inc.
8.10.1 Emergent BioSolutions, Inc. Comapny Information
8.10.2 Emergent BioSolutions, Inc. Business Overview
8.10.3 Emergent BioSolutions, Inc. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Emergent BioSolutions, Inc. Varicella Live Vaccine Product Portfolio
8.10.5 Emergent BioSolutions, Inc. Recent Developments
8.11 Daiichi Sankyo
8.11.1 Daiichi Sankyo Comapny Information
8.11.2 Daiichi Sankyo Business Overview
8.11.3 Daiichi Sankyo Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Daiichi Sankyo Varicella Live Vaccine Product Portfolio
8.11.5 Daiichi Sankyo Recent Developments
8.12 CSL Limited
8.12.1 CSL Limited Comapny Information
8.12.2 CSL Limited Business Overview
8.12.3 CSL Limited Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 CSL Limited Varicella Live Vaccine Product Portfolio
8.12.5 CSL Limited Recent Developments
8.13 Biological E
8.13.1 Biological E Comapny Information
8.13.2 Biological E Business Overview
8.13.3 Biological E Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Biological E Varicella Live Vaccine Product Portfolio
8.13.5 Biological E Recent Developments
8.14 Bavarian Nordic
8.14.1 Bavarian Nordic Comapny Information
8.14.2 Bavarian Nordic Business Overview
8.14.3 Bavarian Nordic Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Bavarian Nordic Varicella Live Vaccine Product Portfolio
8.14.5 Bavarian Nordic Recent Developments
8.15 Astellas Pharma Inc.
8.15.1 Astellas Pharma Inc. Comapny Information
8.15.2 Astellas Pharma Inc. Business Overview
8.15.3 Astellas Pharma Inc. Varicella Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Astellas Pharma Inc. Varicella Live Vaccine Product Portfolio
8.15.5 Astellas Pharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Varicella Live Vaccine Value Chain Analysis
9.1.1 Varicella Live Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Varicella Live Vaccine Production Mode & Process
9.2 Varicella Live Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Varicella Live Vaccine Distributors
9.2.3 Varicella Live Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.